A young child holding the finger of an elderly person with wrinkled skin.

Building a Legacy of Improved Care

The first venture fund built to invest across the full spectrum of autoimmune disease.

$0B+
MARKET SIZE
0M
AMERICANS AFFECTED
0%
WOMEN
0 yrs
AVG. DIAGNOSIS WAIT

Current Care

Current care is fragmented across medical specialties. On average, patients spend 4.5+ years seeking a diagnosis, with additional delays in care as symptoms worsen.

Patient Population

Autoimmune diseases affect an estimated 24 to 50 million Americans, and 25% of patients live with two or more co-occurring autoimmune diseases.

80% Women

Women make up the large majority of autoimmune patients, yet immune-mediated disease remains under-framed in women’s health.

The Problem

Sources: Autoimmune Association, Benaroya Research Institute.

Sources: Autoimmune Association, Business Research Insights, NIH National Institute of Allergy and Infectious Diseases.

WHY NOW

Three fields converging on the same patients

Immunology

Breakthroughs in CAR-T, Treg biology, diagnostics, AI-enabled target discovery, and clinical trial design are moving autoimmunity from broad immunosuppression toward immune reset.

Longevity

Aging biology reframes autoimmunity as a problem of declining immune resilience, opening the door to longer-lasting, restorative interventions.

Women's Health

Sex-based immune differences, including the X chromosome and hormones, help explain women's higher autoimmune burden and reveal new treatment opportunities.

The Investment Opportunity

The Autoimmune Fund backs companies that connect the dots across the immune system in prediction, monitoring, diagnosis, treatment, care access, and remission to improve patient care over the next decade.

Prediction
Monitoring
Diagnosis
Treatment
Most capital here
Care Access
Remission

For Families

The moment is now. More people need better solutions for autoimmune disease, and advances in science are making them possible. This is a chance to help people live better, to open doors that have never existed in care and treatment, and to build something that outlasts any one diagnosis: a legacy of better health for this and future generations.

The Autoimmune Fund backs the companies that can bring those solutions to patients sooner and improve outcomes for the millions of families still waiting.

Give us 30 minutes, and we’ll show you what we see.